28 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
therapies are eligible for intensive guidance from the FDA on an efficient drug development program, organizational commitment to the development
ARS
42ca foqi4
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
jqj97b6
18 Apr 23
Preliminary proxy
7:59am
8-K
EX-99.1
y0vsa y93
2 Aug 22
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors
8:33am
8-K
EX-99.1
zv2cpled
16 Mar 22
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
4:15pm
S-3ASR
x8m4l
10 Nov 21
Automatic shelf registration
5:19pm
8-K
EX-99.1
v9ffv
10 Nov 21
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
4:12pm
DEF 14A
vtuahe8h40j 5mdgoi
26 Apr 21
Definitive proxy
4:22pm
10-K
rsz5j
11 Mar 21
Annual report
4:19pm
424B4
8q7wpu
2 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
jfsbdnjrv6b
28 Sep 20
IPO registration (amended)
6:07am
S-1
EX-10.11
vsj6mh8khbk6g
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.13
ly1iubglo78h8z3l l7b
10 Sep 20
IPO registration
5:26pm